WILMINGTON, Del., Sept. 23 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva's Motion for Summary Judgment of no infringement in the PULMICORT RESPULES(R) (budesonide inhalation suspension) patent litigation. The court also announced that a trial date will be scheduled and is likely to be in January of 2009. AstraZeneca remains focused on preparing for this trial and is confident in the strength of the intellectual property protecting PULMICORT RESPULES. In October of 2005, AstraZeneca announced that it had filed a lawsuit in the US District Court for the District of New Jersey against IVAX Pharmaceuticals, Inc. (now known as Teva Pharmaceutical Industries Ltd.) for patent infringement. The lawsuit is the result of an abbreviated New Drug Application (ANDA) filed by Teva with the US Food and Drug Administration (FDA) concerning its intent to market a generic version of AstraZeneca's PULMICORT RESPULES in the US prior to the expiration of AstraZeneca's patents in 2018, with pediatric exclusivity extending to 2019. The FDA has not approved a generic form of PULMICORT RESPULES, and has not yet responded to AstraZeneca's Citizen Petition, filed in 2006. The Petition outlined AstraZeneca's willingness to work with the FDA to ensure that any follow-on budesonide inhalation suspension product is as safe and effective as PULMICORT RESPULES. About AstraZeneca AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. DATASOURCE: AstraZeneca CONTACT: Media Enquiries UK, Neil McCrae, +44 207 304 5045 (24 hours), or Chris Sampson, +44 20 7304 5130 (24 hours); Media Enquiries US, Emily Denney, +1-302-885-3451; Investor Enquiries UK, Jonathan Hunt, +44 207 304 5087, Cell, +44 7775 704032, Mina Blair, +44 20 7304 5084, Cell, +44 7718 581021, or Karl Hard, +44 207 304 5322, Cell, +44 7789 654364; Investor Enquiries US, Ed Seage, +1-302-886-4065, Cell, +1-302-373-1361, Jorgen Winroth, +1-212-579-0506, Cell, +1-917-612-4043, or Peter Vozzo (MedImmune), +1-301-398-4358, Cell, +1-301-252-7518 Web site: http://www.astrazeneca-us.com/ Company News On-Call: http://www.prnewswire.com/comp/985887.html

Copyright